RxDoctor Payments Data

Lydia Klufas, MD

Dermatology · Cumberland, RINPI 1952406951

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.7% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 48.8% of the total.

$2,155in general payments, 2019–2025

Across 82 payments — averaging $26.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • LEO Pharma Inc.$498
  • AbbVie$216
  • Lilly USA, LLC$186
  • Janssen Scientific Affairs, LLC$97
  • Sanofi$53
  • plus $54 from 2 others

What the payments were for

  • Food & beverage$1,95591%
  • Education$2009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,155 in reported general payments places this provider in the 55th percentile of 61 dermatology providers in Rhode Island.

See all dermatology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$48,376
Medicare patients
183
Services billed
721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib13$80,694
Dupixent PenDupilumab14$61,767
Fluorouracil64$3,462
Clobetasol Propionate83$2,773
Ketoconazole82$1,110
Metronidazole13$760
ValacyclovirValacyclovir Hcl29$584
Doxycycline Hyclate25$460
Triamcinolone Acetonide19$343
Minocycline Hcl15$259
Prednisone23$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$216$80,69413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 61 dermatology providers in Rhode Island.

Other dermatology in Cumberland

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →